Litcius/Paper detail

LBA44 Primary results of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations: WJOG9717L study

Hirotsugu Kenmotsu, Kazushige Wakuda, Keita Mori, T. Kato, Shunichi Sugawara, Keisuke Kirita, Isamu Okamoto, Koichi Azuma, Kazumi Nishino, Shunsuke Teraoka, Ryo Koyama, Ken Masuda, Hidetoshi Hayashi, Ryo Toyozawa, Satoru Miura, Yuki Sato, Kazuhiko Nakagawa, Nobuyuki Yamamoto, Toshiaki Takahashi

2021Annals of Oncology17 citationsDOI

Topics & Concepts

OsimertinibMedicineBevacizumabLung cancerOncologyInternal medicinePhases of clinical researchCancerChemotherapyEpidermal growth factor receptorErlotinibLung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentColorectal Cancer Treatments and Studies
LBA44 Primary results of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations: WJOG9717L study | Litcius